- Home
- PCOR vs PCVX Comparison
PCOR vs PCVX Comparison
Compare PCOR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCOR | PCVX |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.0B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCOR | PCVX |
|---|---|---|
| Price | $49.80 | $50.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | $74.19 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 2.7M | 1.6M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,322,509,000.00 | N/A |
| Revenue This Year | $15.24 | N/A |
| Revenue Next Year | $12.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.83 | N/A |
| 52 Week Low | $45.02 | $29.10 |
| 52 Week High | $82.32 | $65.00 |
Technical Indicators
Market Signals| Indicator | PCOR | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 43.40 |
| Support Level | $46.48 | $41.52 |
| Resistance Level | $59.42 | $56.04 |
| Average True Range (ATR) | 2.28 | 1.97 |
| MACD | 0.16 | 0.17 |
| Stochastic Oscillator | 57.05 | 54.97 |
Price Performance
Historical ComparisonAbout PCOR Procore Technologies Inc.
Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.